ProCE Banner Activity

Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2022

Slideset Download
Conference Coverage

Read expert faculty members’ summaries of HBV, HDV, and HCV studies, including data on HBV therapy during pregnancy, HBV therapeutic vaccines and progress toward an HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and current status of the cascade of care.

Released: November 16, 2022

Share

Faculty

Nancy Reau

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Stefan Zeuzem

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Nancy Reau, MD

Professor of Medicine
Richard B. Capps Chair of Hepatology
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Rush University Medical Center 
Chicago, Illinois

Nancy Reau, MD: consultant/advisor: AbbVie, Antios, Arbutus, Gilead Sciences, Intercept, Salix; researcher: AbbVie, Gilead Sciences, Intercept.

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD: consultant/advisor/speaker: AbbVie, BioMarin, Gilead Sciences, GlaxoSmithKline, Intercept, Janssen, MSD/Merck, Novo Nordisk, SoBi.